Outcomes of vitrectomy in severe complications of proliferative diabetic retinopathy

Outcomes of vitrectomy in severe complications of proliferative diabetic retinopathy

Dorota Borowicz, Dominika Nowakowska, Edyta Koman, Katarzyna Nowomiejska, Robert Rejdak

Department of General Ophthalmology, Medical University in Lublin, Lublin, Poland

ABSTRACT

INTRODUCTION. The aim of our study is to describe the anatomical and functional results of pars plana vitrectomy (PPV) among diabetic patients treated due to tractional retinal detachment (TRD) or non-clearing vitreous haemorrhage (VH).

MATERIALS AND METHODS. A retrospective analysis was made of clinical data of 45 eyes treated with 23G PPV for TRD (17 eyes) or VH (28 eyes). Preoperative and final visual outcomes and postoperative complications were recorded. The mean follow-up period was 12 months.

RESULTS. The postoperative visual acuity (VA) improved significantly in 60% of eyes, but remained unchanged or was worse in 40%. Improvement of VA was more pronounced in the VH group. PPV was performed with silicone oil tamponade in 66.5%, air tamponade in 29%, and gas tamponade in 4.5%. Postoperative complications included: retinal re-detachment (seven eyes), secondary glaucoma (nine eyes), and recurrent VH (two eyes).

CONCLUSIONS. PPV is an effective treatment method of complications of severe proliferative diabetic retinopathy inter alia the TRD and VH. Because surgical management of TRD and VH is demanding, anatomical and functional results are limited by complications.

KEY WORDS: proliferative diabetic retinopathy, vitreous haemorrhage, tractional retinal detachment, vitrectomy

Ophthalmol J 2017; Vol. 2, No. 1, 17–21

INTRODUCTION

Diabetes mellitus is a common chronic metabolic disease wherein the frequency of morbidity increases. The common complications of severe proliferative diabetic retinopathy (PDR) include vitreous haemorrhage (VH), as well as tractional retinal detachment (TRD). Both are indications for vitreoretinal surgery [1].

The concept of pars plana vitrectomy (PPV) began in 1971 by Machemer [2] and was first introduced with 20 G instrumentation in 1972 by O’Malley and Heintz [3]. Since then, the surgical instrumentation has been permanently improved. In 2005, Eckardt developed the 23 G instrumentation [4]. Vitrectomy instruments are now available also in 25 and 27 gauge, which are better for navigation. The cutting speeds are increasing (up to 7500-8000 cuts per minute), which allows extremely precise cutting. The combination of high cutting speeds and small gauge instruments allows successful surgery in severe complications of PDR. PPV gives the possibility of removal of the fibrovascular tissue and blood from the vitreous cavity [5, 6]. However, there is a risk of surgically induced complications, such as bleeding and VH, iatrogenic retinal breaks, recurrent RD, and glaucoma.

This article describes the evaluation of the results and complication rates among diabetic patients treated with PPV due to TRD or VH.

MATERIALS AND METHODS

A retrospective analysis was performed on 45 eyes of 41 patients with PDR, who underwent surgery for the complications of PDR, TRD, or VH, in the Department of General Ophthalmology of Medical University of Lublin in Poland. The surgeries were conducted between January 2012 and December 2015. All the patients were informed about the possible complications and everyone signed the agreement. The inclusion criteria were as follows:

  • presence of TRD or

  • non-clearing VH for more than three months.

Collected medical data were as follows: the type of diabetes, the duration of diabetes, the rubeosis iridis or the cataract presence, type of the tamponade used during PPV, preoperative and final best corrected visual acuity (BCVA), and postoperative complications, e.g.: secondary glaucoma, recurrent TRD, or recurrent VH. The main result measures were final visual outcomes and surgical complications. Each patient underwent a full ophthalmic examination, including BCVA testing with the Snellen method, slit lamp examination, measurement of intraocular pressure, and ultrasonography type B (Fig. 1). Snellen visual acuity records were converted to the logarithm of the minimum angle of resolution (LogMAR) value for statistical analysis.

Outcomes of vitrectomy in severe complications of proliferative diabetic retinopathy

FIGURE 1. Tractional retinal detachment (A); vitreous haemorrhage in ultrasonography (B) – B scan

The schedule of postoperative examinations was as follows: first day, 2 weeks, 6 weeks, and 4, 6, 9, 12, 15, and 18 months after surgery.

PPV is gaining popularity in the treatment of surgical vitreoretinal conditions because it may give faster recovery, but it requires a conjunctival peritomy.

Statistical analyses were performed using GraphPad Prism 5 software.

SURGICAL TECHNIQUE

Standard 23 G PPV was performed in local or general anaesthesia using the Constellation system (Alcon, Fort Worth, Texas, US). Complete PPV with assistance of triamcinolone and scleral indenting was performed. In order to avoid retinal damage, posterior vitreous detachment was not performed on the posterior pole. ILM peeling after indocyanine green (ICG) was performed if tractions were present in the posterior pole. The tractional membranes were removed bimanually using delineation and segmentation techniques. Panretinal laser coagulation was performed intraoperatively in each case. At the end of surgery, air, gas, or silicone oil was used as a tamponade. Sclerotomies were checked for leakage, and if needed, a Vicryl suture was applied (Fig. 2).

Outcomes of vitrectomy in severe complications of proliferative diabetic retinopathy

FIGURE 2. Intraoperative photographs: A. Shaving the vitreous base during the vitrectomy; B. Removing fibrovascular tissue in the posterior pole; C. Photocoagulation of the peripheral retina

RESULTS

The study included 45 eyes of 41 patients with complications for PDR: TRD (17 eyes, i.e. 38%) or VH (i.e. 28 eyes, i.e. 62%). The cohort included 23 men (57%) and 18 women (43%) aged from 25 to 84 years. Eight (20%) patients were diagnosed with type I diabetes and 33 (80%) patients with type 2 diabetes. The mean duration of diabetes was 14.5 years (range 1–34 years). Neovascularisation of the iris was recognised in eight eyes (18%). Laser endophotocoagulation was performed in all eyes before PPV. Preoperative BCVA was between 20/40 and 20/400 in 13 eyes (29%), counting fingers in 10 eyes (22%), and hand movements or light perception in 22 eyes (49%). The mean follow-up period was 12 months. In 11 patients (i.e. 26%) an intraocular lens was implanted during PPV (one patient had aphakia), and 30 patients (73%) had pseudophakia before PPV. In 12 cases (27%) ILM peeling was performed after dying with ICG during PPV. The primary PPV was performed with gas tamponade in two eyes (i.e. 4.5%), silicone oil tamponade in 30 eyes (i.e. 66.5%), and air tamponade in 13 eyes (i.e. 29%). The postoperative BCVA improved significantly in 27 eyes (60%) and remained unchanged or was worse in 18 eyes (40%); however, visual acuity was hand movements or light perception in these eyes. The preoperative logMAR BCVA changed from 1.64 ± 0.07 to 1.41 ± 0.08 postoperatively (Fig. 3). The preoperative logMAR BCVA changed from 1. 71 ± 0.12 to 1.69 ± 0.14 postoperatively among patients with I type diabetes. The preoperative logMAR BCVA changed from 1.80 ± 0.09 to 1.40 ± 0.10 postoperatively among patients with II type diabetes (Fig. 4). The preoperative logMAR BCVA changed from 1. 39 ± 0.66 to 1.26 ± 0.56 postoperatively among patients with TRD. The preoperative logMAR BCVA changed from 1.90 ± 0.07 to 1.65 ± 0.12 postoperatively among patients with VH (Fig. 5).

Outcomes of vitrectomy in severe complications of proliferative diabetic retinopathy

FIGURE 3. Postoperative (post-OP) versus preoperative (pre-OP) visual acuity (LogMAR)

Outcomes of vitrectomy in severe complications of proliferative diabetic retinopathy

FIGURE 4. Comparison of preoperative (pre-OP) and postoperative (post-OP) visual acuity depending on the type of diabetes (type 1 and 2)

Outcomes of vitrectomy in severe complications of proliferative diabetic retinopathy

FIGURE 5. Comparison of preoperative (pre-OP) and postoperative (post-OP) visual acuity in two groups: with vitreous haemorrhage and tractional retinal detachment

IOP was elevated after PPV in nine eyes (eight eyes with silicone oil tamponade and one eye with gas tamponade) and was managed with topical antiglaucomatous drugs. Secondary TRD was observed in seven eyes after PPV with silicone oil tamponade, and in two cases re-VH appeared in patients with silicone oil tamponade.

DISCUSSION

Diabetes is a systemic disease with many systemic vascular complications. Glycaemic, blood pressure and cholesterol control should be optimised before surgery with the internist. Prolonged hyperglycaemia in diabetes leads to an increased permeability in retinal vessels. These changes may lead to hard or soft exudates, macular oedema, and ischaemia, which leads to development of neovascularisation and the formation of fibrovascular membranes. The fibrovascular complex may contract and can result in tractional detachment of the retina. The worst complications of diabetes mellitus are TRD and VH. These complications are major causes of vision loss in patients with PDR.

Surgical management of these complications of proliferative diabetic retinopathy remains one of the most complex and challenging vitreo-retinal procedures.

The results of this study showed that PPV leads to significant vision improvement at the end of the follow-up, both in TRD and VH. Visual improvement was observed in 60% of patients and was more pronounced in the VH group. In a study by Quamar VA improved in 75% of patients after PPV without tamponade [7].

The major complication associated with PPV is recurrent VH, which causes visual impairment and reoperation. The incidence of recurrent VH in PDR was reported in 13–54% of cases [4–7]; in our study this incidence was 11%.

In our study, re-TRD was observed in 41% and the reattachment rate was 65%. In the study by Quamar the re-TRD was in 50%, which were successfully treated by PPV without the use of an ocular tamponade in 92% [7].

Silicone oil or intraocular gases were almost routinely used after PPV for severe TRD [8, 9]. In our study silicone oil was given as a tamponade in 66.5%, air tamponade in 29%, and gas tamponade in 4.5%. Silicone oil enables stable retina at the time of primary vitrectomy. Moreover, using silicone oil avoids loss of vision from re-bleeds and maintains long-term tamponade in TRD.

In the present study the results of surgical treatment of VH and TRD were analysed together. In most of the studies the results are assessed in one group only.

Another important postoperative complication was elevated IOP in nine cases (20%), Sternfeld et al. described similar findings in their retrospective studies of vitrectomised eyes [10].

The another postoperative complication is hypotony. In our study we did not document a case of hypotony. Sternfeld et al. presented 16% of patients after PPV with hypotony [10].

PPV is an effective treatment method of complications of PDR inter alia the TRD and VH sustained over three months. The best benefit from vitrectomy was found in type 1 diabetics, who tended to be younger and had more severe disease.

Intraoperative and postoperative complications can depend on the severity and duration of the disease, and control of the blood glucose.

In conclusion, patients with severe complications of diabetic retinopathy such as VH or TRD can benefit from PPV, although complications may affect the final anatomical and functional results.

REFERENCES

  1. Ho T, Smiddy WE, Flynn HW. Vitrectomy in the management of diabetic eye disease. Surv Ophthalmol. 1992; 37(3): 190–202, indexed in Pubmed: 1475753.

  2. Machemer R, Buettner H, Parel JM, et al. Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol. 1971; 75(4): 813–820, indexed in Pubmed: 5566980.

  3. O’Malley C, Heintz RM. Vitrectomy via the pars plana--a new instrument system. Trans Pac Coast Otoophthalmol Soc Annu Meet. 1972; 53: 121–137, indexed in Pubmed: 4659474.

  4. Heimann K, Dahl B, Dimopoulos S, et al. Pars plana vitrectomy and silicone oil injection in proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 1989; 227(2): 152–156, indexed in Pubmed: 2470655.

  5. Newman DK. Surgical management of the late complications of proliferative diabetic retinopathy. Eye (Lond). 2010; 24(3): 441–449, doi: 10.1038/eye.2009.325, indexed in Pubmed: 20139916.

  6. Oshima Y, Shima C, Wakabayashi T, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology. 2009; 116(5): 927–938, doi: 10.1016/j.ophtha.2008.11.005, indexed in Pubmed: 19269033.

  7. Dikopf MS, Patel KH, Setlur VJ, et al. Surgical outcomes of 25-gauge pars plana vitrectomy for diabetic tractional retinal detachment. Eye (Lond). 2015; 29(9): 1213–1219, doi: 10.1038/eye.2015.126, indexed in Pubmed: 26183284.

  8. Abunajma MA, Al-Dhibi H, Abboud EB, et al. The outcomes and prognostic factors of vitrectomy in chronic diabetic traction macular detachment. Clin Ophthalmol. 2016; 10: 1653–1661, doi: 10.2147/OPTH.S98555, indexed in Pubmed: 27616879.

  9. Sternfeld A, Axer-Siegel R, Stiebel-Kalish H, et al. Advantages of diabetic tractional retinal detachment repair. Clin Ophthalmol. 2015; 9: 1989–1994, doi: 10.2147/OPTH.S90577, indexed in Pubmed: 26604667.

  10. Sharma T, Fong A, Lai TY, et al. Surgical treatment for diabetic vitreoretinal diseases: a review. Clin Exp Ophthalmol. 2016; 44(4): 340–354, doi: 10.1111/ceo.12752, indexed in Pubmed: 27027299.

CORRESPONDING AUTHOR:

Dorota Borowicz, Department of General Ophthalmology, Medical University in Lublin, Chmielna 1 St., 20–079 Lublin, Poland, e-mail: dorotajjj2@wp.pl

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, 73 Świętokrzyska St., 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl